Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 11/20 | 0.48 |
| ▸ | CES1 | P23141 | 10/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL361501 | 0.79 | — | — | |
| SCHEMBL29599682 | 0.79 | — | — | |
| SCHEMBL27970428 | 0.76 | MAPT (0.51) | RAB9AMAPTNPC1KDM4EKMT2A | |
| Benzil SCHEMBL27757984 | 0.72 | CES2 (0.82) | CES2CES1RAB9AMAPTTDP1 | |
| Benzil SCHEMBL27655380 | 0.70 | CES2 (0.88) | CES2CES1RAB9AMAPTTDP1 | |
| Benzil SCHEMBL2234045 | 0.70 | CES2 (0.88) | CES2CES1RAB9AMAPTKDM4E | |
| Benzil SCHEMBL4832229 | 0.70 | CES2 (0.88) | CES2CES1RAB9AMAPTTDP1 | |
| Benzil SCHEMBL66 | 0.69 | CES2 (1.00) | CES2CES1RAB9AMAPTKDM4E | |
| Benzil SCHEMBL9517636 | 0.69 | CES2 (1.00) | CES2CES1RAB9AMAPTKDM4E | |
| Benzil SCHEMBL2156589 | 0.69 | CES2 (1.00) | CES2CES1RAB9AMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593452-B1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2017-01-18 | — | — | EP | disclosed |
| US-9132127-B2 | Substituted pyrido[2,3-B]pyrazines as IP receptor agonists | NOVARTIS AG (CH) | 2015-09-15 | — | — | US | disclosed |
| US-20140243346-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2014-08-28 | — | — | US | disclosed |
| US-8754085-B2 | Pyrido[2,3-b]pyrazine compounds useful as IP receptor agonist | NOVARTIS AG (CH) | 2014-06-17 | — | — | US | disclosed |
| EP-2593452-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | Novartis AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| US-20130102611-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2013-04-25 | — | — | US | disclosed |
| WO-2012007539-A9 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012007539-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243346-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | PTGIR, ACVR1, PTGFR | CES2 4710/4885CES1 3962/4885RAB9A 1600/4885 |
| US-20130102611-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | PTGIR, ACVR1, PTGFR | CES2 4710/4885CES1 3962/4885RAB9A 1600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.